LMP400 recently demonstrated synergistic cell killing activity against PTEN-null glioblastoma cells when combined with the PARP inhibitor niraparib [50], results that led the FDA to grant orphan drug designation to LMP400 for use in patients with glioma. Here, PARP1 is linked to central nervous system cancer.